Classification Term: 170714

Purine alkaloids (ontology term: 03f79aafe797e767572e187a82bbe222)

found 126 associated metabolites at sub_class metabolite taxonomy ontology rank level.

Ancestor: Pseudoalkaloids (transamidation)

Child Taxonomies: There is no child term of current ontology term.

Caffeine

1,3,7-trimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

C8H10N4O2 (194.0804)


Caffeine is a methyl xanthine alkaloid that is also classified as a purine. Formally, caffeine belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety. Caffeine is chemically related to the adenine and guanine bases of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). It is found in the seeds, nuts, or leaves of a number of plants native to Africa, East Asia and South America and helps to protect them against predator insects and to prevent germination of nearby seeds. The most well-known source of caffeine is the coffee bean. Caffeine is the most widely consumed psychostimulant drug in the world. 85\\\% of American adults consumed some form of caffeine daily, consuming 164 mg on average. Caffeine is mostly is consumed in the form of coffee. Caffeine is a central nervous system stimulant that reduces fatigue and drowsiness. At normal doses, caffeine has variable effects on learning and memory, but it generally improves reaction time, wakefulness, concentration, and motor coordination. Caffeine is a proven ergogenic aid in humans. Caffeine improves athletic performance in aerobic (especially endurance sports) and anaerobic conditions. Moderate doses of caffeine (around 5 mg/kg) can improve sprint performance, cycling and running time trial performance, endurance and cycling power output (PMID: 32551869). At intake levels associated with coffee consumption, caffeine appears to exert most of its biological effects through the antagonism of the A1 and A2A subtypes of the adenosine receptor. Adenosine is an endogenous neuromodulator with mostly inhibitory effects, and adenosine antagonism by caffeine results in effects that are generally stimulatory. Some physiological effects associated with caffeine administration include central nervous system stimulation, acute elevation of blood pressure, increased metabolic rate, and diuresis. A number of in vitro and in vivo studies have demonstrated that caffeine modulates both innate and adaptive immune responses. For instance, studies indicate that caffeine and its major metabolite paraxanthine suppress neutrophil and monocyte chemotaxis, and also suppress production of the pro-inflammatory cytokine tumor necrosis factor (TNF) alpha from human blood. Caffeine has also been reported to suppress human lymphocyte function as indicated by reduced T-cell proliferation and impaired production of Th1 (interleukin [IL]-2 and interferon [IFN]-gamma), Th2 (IL-4, IL-5) and Th3 (IL-10) cytokines. Studies also indicate that caffeine suppresses antibody production. The evidence suggests that at least some of the immunomodulatory actions of caffeine are mediated via inhibition of cyclic adenosine monophosphate (cAMP)-phosphodiesterase (PDE), and consequential increase in intracellular cAMP concentrations. Overall, these studies indicate that caffeine, like other members of the methylxanthine family, is largely anti-inflammatory in nature, and based on the pharmacokinetics of caffeine, many of its immunomodulatory effects occur at concentrations that are relevant to normal human consumption. (PMID: 16540173). Caffeine is rapidly and almost completely absorbed in the stomach and small intestine and distributed to all tissues, including the brain. Caffeine metabolism occurs primarily in the liver, where the activity of the cytochrome P450 isoform CYP1A2 accounts for almost 95\\\% of the primary metabolism of caffeine. CYP1A2-catalyzed 3-demethylation of caffeine results in the formation of 1,7-dimethylxanthine (paraxanthine). Paraxanthine may be demethylated by CYP1A2 to form 1-methylxanthine, which may be oxidized to 1-methyluric acid by xanthine oxidase. Paraxanthine may also be hydroxylated by CYP2A6 to form 1,7-dimethyluric acid, or acetylated by N-acetyltransferase 2 (NAT2) to form 5-acetylamino-6-formylamino-3-methyluracil, an unstable compound that may be deformylated nonenzymatically to form ... Caffeine appears as odorless white powder or white glistening needles, usually melted together. Bitter taste. Solutions in water are neutral to litmus. Odorless. (NTP, 1992) Caffeine is a trimethylxanthine in which the three methyl groups are located at positions 1, 3, and 7. A purine alkaloid that occurs naturally in tea and coffee. It has a role as a central nervous system stimulant, an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor, an adenosine receptor antagonist, an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor, a ryanodine receptor agonist, a fungal metabolite, an adenosine A2A receptor antagonist, a psychotropic drug, a diuretic, a food additive, an adjuvant, a plant metabolite, an environmental contaminant, a xenobiotic, a human blood serum metabolite, a mouse metabolite, a geroprotector and a mutagen. It is a purine alkaloid and a trimethylxanthine. Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine]. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection. The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely. Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants. Caffeine is a Central Nervous System Stimulant and Methylxanthine. The physiologic effect of caffeine is by means of Central Nervous System Stimulation. Caffeine is xanthine alkaloid that occurs naturally in seeds, leaves and fruit of several plants and trees that acts as a natural pesticide. Caffeine is a major component of coffee, tea and chocolate and in humans acts as a central nervous system (CNS) stimulant. Consumption of caffeine, even in high doses, has not been associated with elevations in serum enzyme elevations or instances of clinically apparent liver injury. Caffeine is a natural product found in Mus musculus, Herrania cuatrecasana, and other organisms with data available. Caffeine is a methylxanthine alkaloid found in the seeds, nuts, or leaves of a number of plants native to South America and East Asia that is structurally related to adenosine and acts primarily as an adenosine receptor antagonist with psychotropic and anti-inflammatory activities. Upon ingestion, caffeine binds to adenosine receptors in the central nervous system (CNS), which inhibits adenosine binding. This inhibits the adenosine-mediated downregulation of CNS activity; thus, stimulating the activity of the medullary, vagal, vasomotor, and respiratory centers in the brain. This agent also promotes neurotransmitter release that further stimulates the CNS. The anti-inflammatory effects of caffeine are due the nonselective competitive inhibition of phosphodiesterases (PDEs). Inhibition of PDEs raises the intracellular concentration of cyclic AMP (cAMP), activates protein kinase A, and inhibits leukotriene synthesis, which leads to reduced inflammation and innate immunity. Caffeine is the most widely consumed psychostimulant drug in the world that mostly is consumed in the form of coffee. Whether caffeine and/or coffee consumption contribute to the development of cardiovascular disease (CVD), the single leading cause of death in the US, is uncle... Component of coffee beans (Coffea arabica), many other Coffea subspecies, chocolate (Theobroma cacao), tea (Camellia thea), kolanut (Cola acuminata) and several other Cola subspecies and several other plants. It is used in many cola-type beverages as a flavour enhancer. Caffeine is found in many foods, some of which are black cabbage, canola, jerusalem artichoke, and yellow bell pepper. A trimethylxanthine in which the three methyl groups are located at positions 1, 3, and 7. A purine alkaloid that occurs naturally in tea and coffee. [Raw Data] CBA01_Caffeine_pos_50eV.txt [Raw Data] CBA01_Caffeine_pos_20eV.txt [Raw Data] CBA01_Caffeine_pos_40eV.txt [Raw Data] CBA01_Caffeine_pos_10eV.txt [Raw Data] CBA01_Caffeine_pos_30eV.txt Caffeine. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=58-08-2 (retrieved 2024-06-29) (CAS RN: 58-08-2). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

3,7-Dimethyluric acid

3,7-dimethyl-2,3,6,7,8,9-hexahydro-1H-purine-2,6,8-trione

C7H8N4O3 (196.0596)


3,7-Dimethyluric acid is a methyl derivative of uric acid, found occasionally in human urine. 3,7-Dimethyluric is one of the purine components in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. Caffeine is metabolized via successive pathways mainly catalyzed by CYP1A2, xanthine oxidase or N-acetyltransferase-2 to give 14 different metabolites. CYP1A2 activity shows an inter-individual variability among the population. CYP1A2, an isoform of the CYP1A cytochrome P450 super-family, is involved in the metabolism of many drugs and plays a potentially important role in the induction of chemical carcinogenesis. (PMID: 11712316, 15833286, 3506820, 15013152) [HMDB] 3,7-Dimethyluric acid is a methyl derivative of uric acid, found occasionally in human urine. 3,7-Dimethyluric is one of the purine components in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. Caffeine is metabolized via successive pathways mainly catalyzed by CYP1A2, xanthine oxidase or N-acetyltransferase-2 to give 14 different metabolites. CYP1A2 activity shows an inter-individual variability among the population. CYP1A2, an isoform of the CYP1A cytochrome P450 super-family, is involved in the metabolism of many drugs and plays a potentially important role in the induction of chemical carcinogenesis (PMID:11712316, 15833286, 3506820, 15013152).

   

7-Methyladenine

7-Methyl-7H-purin-6-ylamine (acd/name 4.0)

C6H7N5 (149.0701)


7-Methyladenine is part of the base excision repair pathway. In this pathway, alkylated DNA is hydrolysed via the enzyme DNA-3-methyladenine glycosylase II (EC 3.2.2.21), releasing 3-methyladenine, 3-methylguanine, 7-methylguanine and 7-methyladenine. This enzyme is responsible for the hydrolysis of the deoxyribose N-glycosidic bond to excise 3-methyladenine, and 7-methylguanine from the damaged DNA polymer formed by alkylation lesions. Base excision repair (BER) is a cellular mechanism that repairs damaged DNA throughout the cell cycle. Repairing DNA sequence errors is necessary so that mutations are not propagated or to remove lesions that may lead to breaks in the DNA during replication. Single bases in DNA can be chemically mutated, for example by deamination or alkylation, resulting in incorrect base-pairing, and consequently, mutations in the DNA. Base excision repair involves flipping the mutated base out of the DNA helix and repairing the base alone. There are two main enzymes used, DNA glycosylases and AP endonucleases. The DNA glycosylase is used to break the beta-N glycosidic bond to create an AP site. AP endonuclease recognizes this site and nicks the damaged DNA on the 5 side (upstream) of the AP site creating a free 3-OH. DNA polymerase, Pol I (human pol beta), extends the DNA from the free 3-OH using its exonuclease activity to replace the nucleotide of the damaged base, as well as a few downstream, followed by sealing of the new DNA strand by DNA ligase. In mammalian cells, this is done by LigIII in complex with the scaffold protein XRCC1. Usually, BER is divided into short-patch repair (where a single nucleotide is replaced) or long-patch repair (where 2-10 nucleotides are replaced). Mammalian long-patch repair includes PCNA and pol delta/epsilon for nucleotide resynthesis, FEN1 to cut of the flap including the damaged base, and LigI. 7-Methyladenine is part of the base excision repair pathway. In this pathway, alkylated DNA is hydrolysed via the enzyme DNA-3-methyladenine glycosylase II (EC 3.2.2.21), releasing 3-methyladenine, 3-methylguanine, 7-methylguanine and 7-methyladenine. This enzyme is responsible for the hydrolysis of the deoxyribose N-glycosidic bond to excise 3-methyladenine, and 7-methylguanine from the damaged DNA polymer formed by alkylation lesions. (Pathway Commons)

   

Mercaptopurine

GlaxoSmithKline brand OF 6 mercaptopurine

C5H4N4S (152.0157)


Mercaptopurine is only found in individuals that have used or taken this drug. It is an antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem]Mercaptopurine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to thioinosinic acid (TIMP). This intracellular nucleotide inhibits several reactions involving inosinic acid (IMP), including the conversion of IMP to xanthylic acid (XMP) and the conversion of IMP to adenylic acid (AMP) via adenylosuccinate (SAMP). In addition, 6-methylthioinosinate (MTIMP) is formed by the methylation of TIMP. Both TIMP and MTIMP have been reported to inhibit glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme unique to the de novo pathway for purine ribonucleotide synthesis. Experiments indicate that radiolabeled mercaptopurine may be recovered from the DNA in the form of deoxythioguanosine. Some mercaptopurine is converted to nucleotide derivatives of 6-thioguanine (6-TG) by the sequential actions of inosinate (IMP) dehydrogenase and xanthylate (XMP) aminase, converting TIMP to thioguanylic acid (TGMP). L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents

   

trans-zeatin riboside

(2R,3R,4S,5R)-2-(6-{[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.1543)


Trans-zeatin riboside, also known as (E)-N-(4-hydroxy-3-methyl-2-butenyl)adenosine or 9-beta-D-ribofuranosyl-trans-zeatin, is a member of the class of compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Trans-zeatin riboside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Trans-zeatin riboside can be found in a number of food items such as winter squash, plains prickly pear, dill, and common buckwheat, which makes trans-zeatin riboside a potential biomarker for the consumption of these food products. D006133 - Growth Substances > D010937 - Plant Growth Regulators > D003583 - Cytokinins Acquisition and generation of the data is financially supported in part by CREST/JST. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits.

   

lupinate

(S)-2-Amino-3-{[(E)-4-hydroxy-3-methylbut-2-enylamino]purin-9- yl}propanoic acid

C13H18N6O3 (306.144)


   

Discadenine

3-(3-Amino-3-carboxypropyl)-N6-(δ2-isopentenyl)-adenine

C14H20N6O2 (304.1648)


A 6-isopentenylaminopurine having a 3-amino-3-carboxypropyl group attached at the 3-position.

   

Triacanthine

3-(3-methylbut-2-en-1-yl)-3H-purin-6-amine

C10H13N5 (203.1171)


   

Toxoflavin

Toxoflavine

C7H7N5O2 (193.06)


A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7.

   

Cis-zeatin

(Z)-2-Methyl-4-(1H-purin-6-ylamino)but-2-en-1-ol

C10H13N5O (219.112)


The cis-isomer of zeatin. Acquisition and generation of the data is financially supported by the Max-Planck-Society

   

cis-zeatin riboside

(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(Z)-4-hydroxy-3-methylbut-2-enyl]amino]purin-9-yl]oxolane-3,4-diol

C15H21N5O5 (351.1543)


   

6-Dimethylaminopurine

N,N-dimethyl-7H-purin-6-amine

C7H9N5 (163.0858)


6-Dimethylaminopurine, also known as 6,6-dimethyladenine or 6-DMAP, belongs to the class of organic compounds known as 6-alkylaminopurines. 6-alkylaminopurines are compounds that contain an alkylamine group attached at the 6-position of a purine. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring. 6-Dimethylaminopurine is a puromycin analog that was first identified in the spores of Streptomyces alboniger (PMID: 5019066). It has subsequently been identified in several algae species (PMID: 4206669). 6-DMAP is widely used in the lab as a cell cycle inhibitor and a cyclin dependent kinase inhibitor. It also induces cell apoptosis. 6-DMAP is widely used for oocyte activation in eukaryotic cloning experiments (PMID: 29467049). 6-Dimethylaminopurine is a serine threonine protein kinase inhibitor. It inhibits the germinal vesicle breakdown and the meiotic maturation of oocytes. (PMID 2540051) D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

   

8-Hydroxy-7-methylguanine

2-amino-7-methyl-6,7,8,9-tetrahydro-3H-purine-6,8-dione

C6H7N5O2 (181.06)


8-Hydroxy-7-methylguanine is a modified nucleoside. 8-Hydroxy-7-methylguanine is an endogenous methylated nucleoside found in human fluids; methylated purine bases are present in higher amounts in tumor-bearing patients compared to healthy controls. Human exposure to carcinogenic alkylating agents can lead to the formation of covalently bound adducts in DNA, some of which are excreted in urine as alkylated purines following DNA degradation and repair; the N2 position of guanine is one of the major sites for DNA modification by various carcinogens. Measurements of RNA or DNA catabolites in urine can be used as a measure for the metabolism of each of the three major species of RNA. An accumulation of modified ribonucleosides appears in the serum of uremic patients. (PMID: 3506820, 5961889, 16527824, 16061253, 8043914, 2428556, 7159514, 9607216) [HMDB] 8-Hydroxy-7-methylguanine is a modified nucleoside. 8-Hydroxy-7-methylguanine is an endogenous methylated nucleoside found in human fluids; methylated purine bases are present in higher amounts in tumor-bearing patients compared to healthy controls. Human exposure to carcinogenic alkylating agents can lead to the formation of covalently bound adducts in DNA, some of which are excreted in urine as alkylated purines following DNA degradation and repair; the N2 position of guanine is one of the major sites for DNA modification by various carcinogens. Measurements of RNA or DNA catabolites in urine can be used as a measure for the metabolism of each of the three major species of RNA. An accumulation of modified ribonucleosides appears in the serum of uremic patients. (PMID: 3506820, 5961889, 16527824, 16061253, 8043914, 2428556, 7159514, 9607216).

   

1,3-Dimethyluracil

1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

C6H8N2O2 (140.0586)


1,3-Dimethyluracil is a methyl derivative of uric acid, found occasionally in human urine. 1,3-Dimethyluracil is one of the purine component in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. (PMID: 11712316, 15833286, 3506820) [HMDB] 1,3-Dimethyluracil is a methyl derivative of uric acid, found occasionally in human urine. 1,3-Dimethyluracil is one of the purine component in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. (PMID:11712316, 15833286, 3506820). 1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with Ki of 316.2 μM and 166.4 μM, respectively[1][2].

   

6-Amino-9H-purine-9-propanoic acid

3-(6-amino-9h-purin-9-yl)propanoic acid

C8H9N5O2 (207.0756)


6-Amino-9H-purine-9-propanoic acid is found in mushrooms. 6-Amino-9H-purine-9-propanoic acid is isolated from Lentinus edodes (shiitake

   

Acefylline

2-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-yl)acetic acid

C9H10N4O4 (238.0702)


C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator Acefylline (Theophyllineacetic acid), a xanthine derivative, is an adenosine receptor antagonist. Acefylline is a peptidylarginine deiminase (PAD) activator. Acefylline is also a bronchodilator, which inhibits rat lung cAMP phosphodiesterase isoenzymes[1][2]. Acefylline, a xanthine derivative, is an adenosine receptor antagonist. Acefylline is a peptidylarginine deiminase (PAD) activator. Acefylline is also a bronchodilator and cardiac stimulant that inhibits rat lung cAMP phosphodiesterase isoenzymes. Acefylline can be used in asthma research[1][2][3]. Acefylline (Theophyllineacetic acid), a xanthine derivative, is an adenosine receptor antagonist. Acefylline is a peptidylarginine deiminase (PAD) activator. Acefylline is also a bronchodilator, which inhibits rat lung cAMP phosphodiesterase isoenzymes[1][2].

   

cis-zeatin riboside

2-(6-{[(2Z)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.1543)


Cis-zeatin riboside is a member of the class of compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Cis-zeatin riboside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Cis-zeatin riboside can be found in a number of food items such as american pokeweed, sesbania flower, moth bean, and common chokecherry, which makes cis-zeatin riboside a potential biomarker for the consumption of these food products.

   

Caffeine

1,3,7-trimethylpurine-2,6-dione

C8H10N4O2 (194.0804)


N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BC - Xanthine derivatives D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant CONFIDENCE standard compound; EAWAG_UCHEM_ID 303 EAWAG_UCHEM_ID 303; CONFIDENCE standard compound D - Dermatologicals Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   
   

Acefylline

Acefylline

C9H10N4O4 (238.0702)


C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator Acefylline (Theophyllineacetic acid), a xanthine derivative, is an adenosine receptor antagonist. Acefylline is a peptidylarginine deiminase (PAD) activator. Acefylline is also a bronchodilator, which inhibits rat lung cAMP phosphodiesterase isoenzymes[1][2]. Acefylline, a xanthine derivative, is an adenosine receptor antagonist. Acefylline is a peptidylarginine deiminase (PAD) activator. Acefylline is also a bronchodilator and cardiac stimulant that inhibits rat lung cAMP phosphodiesterase isoenzymes. Acefylline can be used in asthma research[1][2][3]. Acefylline (Theophyllineacetic acid), a xanthine derivative, is an adenosine receptor antagonist. Acefylline is a peptidylarginine deiminase (PAD) activator. Acefylline is also a bronchodilator, which inhibits rat lung cAMP phosphodiesterase isoenzymes[1][2].

   
   

Fervenulin

Fervenulin

C7H7N5O2 (193.06)


   

1,3,7-trimethylisoguanine

1,3,7-trimethylisoguanine

C8H11N5O (193.0964)


A natural product found in Paramuricea clavata and Pseudodistoma cereum.

   

3-(3-methylbut-2-en-1-yl)-3H-purin-6-amine

3-(3-methylbut-2-enyl)-7H-purin-6-imine

C10H13N5 (203.1171)


   

Caffeine

1,3,7-trimethylpurine-2,6-dione

C8H10N4O2 (194.0804)


CONFIDENCE standard compound; INTERNAL_ID 1199; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5866; ORIGINAL_PRECURSOR_SCAN_NO 5861 N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BC - Xanthine derivatives D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant D - Dermatologicals Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 1199; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5880; ORIGINAL_PRECURSOR_SCAN_NO 5879 CONFIDENCE standard compound; INTERNAL_ID 1199; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5893; ORIGINAL_PRECURSOR_SCAN_NO 5892 CONFIDENCE standard compound; INTERNAL_ID 1199; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5916; ORIGINAL_PRECURSOR_SCAN_NO 5911 CONFIDENCE standard compound; INTERNAL_ID 1199; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5923; ORIGINAL_PRECURSOR_SCAN_NO 5921 CONFIDENCE standard compound; INTERNAL_ID 1199; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5924; ORIGINAL_PRECURSOR_SCAN_NO 5922 CONFIDENCE standard compound; INTERNAL_ID 2766 MS2 deconvoluted using MS2Dec from all ion fragmentation data, MetaboLights identifier MTBLS1040; RYYVLZVUVIJVGH-UHFFFAOYSA-N_STSL_0030_Caffeine_0500fmol_180410_S2_LC02_MS02_97; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. MS2 deconvoluted using CorrDec from all ion fragmentation data, MetaboLights identifier MTBLS1040; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 1079 CONFIDENCE standard compound; INTERNAL_ID 50 CONFIDENCE standard compound; INTERNAL_ID 8666 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.568 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.560 CONFIDENCE standard compound; INTERNAL_ID 4089 IPB_RECORD: 3001; CONFIDENCE confident structure

   

mercaptopurine

6-Mercaptopurine

C5H4N4S (152.0157)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents CONFIDENCE standard compound; INTERNAL_ID 2786 KEIO_ID M054

   

trans-Zeatin-O-glucoside

trans-Zeatin-O-glucoside

C16H23N5O6 (381.1648)


Acquisition and generation of the data is financially supported by the Max-Planck-Society

   

6-dimethylaminopurine

N6,N6-dimethyladenine

C7H9N5 (163.0858)


D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

   

3,7-Dimethyluric acid

3,7-dimethyl-9H-purine-2,6,8-trione

C7H8N4O3 (196.0596)


An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trione substituted by methyl groups at N-3 and N-7.

   

1,3-Dimethyluracil

1, 3-Dimethyl-2,4(1H,3H)-pyrimidinedione

C6H8N2O2 (140.0586)


A pyrimidone that is uracil with methyl group substituents at positions 1 and 3. 1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with Ki of 316.2 μM and 166.4 μM, respectively[1][2].

   

Benzyladenine

6-benzylaminopurine

C12H11N5 (225.1014)


D006133 - Growth Substances > D010937 - Plant Growth Regulators 6-Benzylaminopurine (Benzyladenine) is the first cytokinin that causes plant growth and development by stimulating cell division and inhibiting respiratory kinases, thereby prolonging the preservation of green vegetables[1]. 6-Benzylaminopurine is the first cytokinin that causes plant growth and development by stimulating cell division and inhibiting respiratory kinases, thereby prolonging the preservation of green vegetables.

   

8-Hydroxy-7-methylguanine

8-Hydroxy-7-methylguanine

C6H7N5O2 (181.06)


An oxopurine that is guanine with an oxo group at position 8 and a methyl substituent at position 7.

   

3-(9-Adeninyl)propionic acid

3-(6-amino-9h-purin-9-yl)propanoic acid

C8H9N5O2 (207.0756)


   

Thesal

1H-purine-2,6-dione,3,7-dihydro-3,7- dimethyl- (9CI)

C7H8N4O2 (180.0647)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DA - Xanthines C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BD - Xanthine derivatives D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

(2S)-2-amino-4-{6-[(3-methylbut-2-en-1-yl)amino]-3H-purin-3-yl}butanoic acid

(2S)-2-amino-4-{6-[(3-methylbut-2-en-1-yl)amino]-3H-purin-3-yl}butanoic acid

C14H20N6O2 (304.1648)


   

7-Methyladenine

7-Methyl-7H-purin-6-amine

C6H7N5 (149.0701)


Adenine substituted with a methyl group at position N-7.

   

Tetramethyluric acid

1,3,7,9-Tetramethyluric acid

C9H12N4O3 (224.0909)


An oxopurine that is uric acid in which the hydrogens at positions 1,3,7 and 9 are replaced by methyl groups. It is a purine alkaloid that is found in Chinese tea known as kucha (Camellia assamica var. kucha) and exhibits anti-inflammatory and analgesic properties.

   

3-(6-amino-9h-purin-9-yl)propanoic acid

3-(6-aminopurin-9-yl)propanoic acid

C8H9N5O2 (207.0756)


   

2-(3-methylbut-3-en-1-yl)-3h-purin-6-amine

2-(3-methylbut-3-en-1-yl)-3h-purin-6-amine

C10H13N5 (203.1171)


   

2-{6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]purin-9-yl}-6-(hydroxymethyl)oxane-3,4,5-triol

2-{6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]purin-9-yl}-6-(hydroxymethyl)oxane-3,4,5-triol

C16H23N5O6 (381.1648)


   

(2r,3s,5r)-5-(6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

(2r,3s,5r)-5-(6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

C15H21N5O4 (335.1593)


   

9-(3-methylbut-2-en-1-yl)purin-6-amine

9-(3-methylbut-2-en-1-yl)purin-6-amine

C10H13N5 (203.1171)


   

6-(1-hydroxypropyl)-1,3-dimethylpteridine-2,4-dione

6-(1-hydroxypropyl)-1,3-dimethylpteridine-2,4-dione

C11H14N4O3 (250.1066)


   

6-{[(3,5-dibromo-4-hydroxyphenyl)methyl]amino}-9h-purin-8-ol

6-{[(3,5-dibromo-4-hydroxyphenyl)methyl]amino}-9h-purin-8-ol

C12H9Br2N5O2 (412.9123)


   

1,3-dimethyl-7-(3,7,11,15-tetramethyl-13-oxohexadeca-2,6,10-trien-1-yl)purine-2,6-dione

1,3-dimethyl-7-(3,7,11,15-tetramethyl-13-oxohexadeca-2,6,10-trien-1-yl)purine-2,6-dione

C27H40N4O3 (468.31)


   

5-hydroxy-1,3,7-trimethylpurine-2,6,8-trione

5-hydroxy-1,3,7-trimethylpurine-2,6,8-trione

C8H10N4O4 (226.0702)


   

(2r,3r,4s,5s)-2-(6-{[(2z)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

(2r,3r,4s,5s)-2-(6-{[(2z)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.1543)


   

(2r,3s,4r,5s,6r)-2-(6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-7-yl)-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3s,4r,5s,6r)-2-(6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-7-yl)-6-(hydroxymethyl)oxane-3,4,5-triol

C16H23N5O6 (381.1648)


   

9-(3,7-dimethylocta-2,6-dien-1-yl)-6-hydroxy-3,7-dimethylpurine-2,8-dione

9-(3,7-dimethylocta-2,6-dien-1-yl)-6-hydroxy-3,7-dimethylpurine-2,8-dione

C17H24N4O3 (332.1848)


   

6-imino-1,7-dimethyl-3-(3-methylbuta-1,3-dien-1-yl)purin-2-one

6-imino-1,7-dimethyl-3-(3-methylbuta-1,3-dien-1-yl)purin-2-one

C12H15N5O (245.1277)


   

2-{6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol

2-{6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.1543)


   

trimethylpyrimido[5,4-e][1,2,4]triazine-3,5,7-trione

trimethylpyrimido[5,4-e][1,2,4]triazine-3,5,7-trione

C8H9N5O3 (223.0705)


   

(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-{6-[(3-methylbut-2-en-1-yl)amino]purin-9-yl}oxane-3,4,5-triol

(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-{6-[(3-methylbut-2-en-1-yl)amino]purin-9-yl}oxane-3,4,5-triol

C16H23N5O5 (365.1699)


   

6-[5-(1,3-dimethyl-2,4-dioxopteridin-6-yl)-4-methyl-5-oxopentanoyl]-1,3-dimethylpteridine-2,4-dione

6-[5-(1,3-dimethyl-2,4-dioxopteridin-6-yl)-4-methyl-5-oxopentanoyl]-1,3-dimethylpteridine-2,4-dione

C22H22N8O6 (494.1662)


   

3-[(8-hydroxy-9h-purin-6-yl)amino]propanoic acid

3-[(8-hydroxy-9h-purin-6-yl)amino]propanoic acid

C8H9N5O3 (223.0705)


   

(2s,3s,4r,5s,6s)-2-{[(2e)-4-({9-[(2s,3r,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl}amino)-2-methylbut-2-en-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3s,4r,5s,6s)-2-{[(2e)-4-({9-[(2s,3r,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl}amino)-2-methylbut-2-en-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H31N5O10 (513.2071)


   

(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-{[(2e)-2-methyl-4-(3h-purin-6-ylamino)but-2-en-1-yl]oxy}oxane-3,4,5-triol

(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-{[(2e)-2-methyl-4-(3h-purin-6-ylamino)but-2-en-1-yl]oxy}oxane-3,4,5-triol

C16H23N5O6 (381.1648)


   

2-(hydroxymethyl)-6-{[2-methyl-4-(3h-purin-6-ylamino)but-2-en-1-yl]oxy}oxane-3,4,5-triol

2-(hydroxymethyl)-6-{[2-methyl-4-(3h-purin-6-ylamino)but-2-en-1-yl]oxy}oxane-3,4,5-triol

C16H23N5O6 (381.1648)


   

1,3-dimethyl-7-(3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl)purine-2,6-dione

1,3-dimethyl-7-(3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl)purine-2,6-dione

C27H40N4O3 (468.31)


   

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-(6-{[(2e)-3-methyl-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-en-1-yl]amino}purin-9-yl)oxane-3,4,5-triol

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-(6-{[(2e)-3-methyl-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-en-1-yl]amino}purin-9-yl)oxane-3,4,5-triol

C22H33N5O11 (543.2176)


   

6-[(4s)-5-(1,3-dimethyl-2,4-dioxopteridin-6-yl)-4-methyl-5-oxopentanoyl]-1,3-dimethylpteridine-2,4-dione

6-[(4s)-5-(1,3-dimethyl-2,4-dioxopteridin-6-yl)-4-methyl-5-oxopentanoyl]-1,3-dimethylpteridine-2,4-dione

C22H22N8O6 (494.1662)


   

9-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-3-methylpurin-2-one

9-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-3-methylpurin-2-one

C16H22N4O3 (318.1692)


   

(2r,3r,4s,5s,6r)-2-{[(2e)-4-({9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl}amino)-2-methylbut-2-en-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(2e)-4-({9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl}amino)-2-methylbut-2-en-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H31N5O10 (513.2071)


   

6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]-3h-purin-2-ol

6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]-3h-purin-2-ol

C10H13N5O2 (235.1069)


   

2-(dimethylamino)-7-methylpurin-6-ol

2-(dimethylamino)-7-methylpurin-6-ol

C8H11N5O (193.0964)


   

1,1,1-trimethyl-n-[9-(5-{[(3-methylbut-3-en-1-yl)oxy]methyl}-3,4-bis[(trimethylsilyl)oxy]oxolan-2-yl)purin-6-yl]silanamine

1,1,1-trimethyl-n-[9-(5-{[(3-methylbut-3-en-1-yl)oxy]methyl}-3,4-bis[(trimethylsilyl)oxy]oxolan-2-yl)purin-6-yl]silanamine

C24H45N5O4Si3 (551.2779)


   

1,3-dimethyl-7-[(2e,6e,10e)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,10-trien-1-yl]purine-2,6-dione

1,3-dimethyl-7-[(2e,6e,10e)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,10-trien-1-yl]purine-2,6-dione

C27H40N4O3 (468.31)


   

2-imino-1,3-dimethyl-9h-purin-6-one

2-imino-1,3-dimethyl-9h-purin-6-one

C7H9N5O (179.0807)


   

trans-zeatin-7-β-d-glucoside

trans-zeatin-7-β-d-glucoside

C16H23N5O6 (381.1648)


   

2-(dimethylamino)-7,9-dimethyl-8h-purin-6-ol

2-(dimethylamino)-7,9-dimethyl-8h-purin-6-ol

C9H15N5O (209.1277)


   

6-imino-1,7-dimethyl-3-[(1e)-3-methylbuta-1,3-dien-1-yl]purin-2-one

6-imino-1,7-dimethyl-3-[(1e)-3-methylbuta-1,3-dien-1-yl]purin-2-one

C12H15N5O (245.1277)


   

(6e)-3,9-dimethyl-6-(methylimino)purin-8-ol

(6e)-3,9-dimethyl-6-(methylimino)purin-8-ol

C8H11N5O (193.0964)


   

(2s,3r,4r,5s,6s)-2-(hydroxymethyl)-6-{[(2z)-2-methyl-4-(3h-purin-6-ylamino)but-2-en-1-yl]oxy}oxane-3,4,5-triol

(2s,3r,4r,5s,6s)-2-(hydroxymethyl)-6-{[(2z)-2-methyl-4-(3h-purin-6-ylamino)but-2-en-1-yl]oxy}oxane-3,4,5-triol

C16H23N5O6 (381.1648)


   

2-amino-4-{6-[(3-methylbut-2-en-1-yl)imino]-9h-purin-3-yl}butanoic acid

2-amino-4-{6-[(3-methylbut-2-en-1-yl)imino]-9h-purin-3-yl}butanoic acid

C14H20N6O2 (304.1648)


   

4-(6,8-dihydroxypurin-9-yl)butan-2-one

4-(6,8-dihydroxypurin-9-yl)butan-2-one

C9H10N4O3 (222.0753)


   

2-imino-3h-purine-6,7-diol

2-imino-3h-purine-6,7-diol

C5H5N5O2 (167.0443)


   

6-(2-hydroxy-2-oxo-6h-1,3,2λ⁵-dioxaphosphinin-4-yl)-1,3-dimethylpteridine-2,4-dione

6-(2-hydroxy-2-oxo-6h-1,3,2λ⁵-dioxaphosphinin-4-yl)-1,3-dimethylpteridine-2,4-dione

C11H11N4O6P (326.0416)


   

2-imino-3,7-dimethylpurin-6-ol

2-imino-3,7-dimethylpurin-6-ol

C7H9N5O (179.0807)


   

6-acetyl-1,3-dimethylpteridine-2,4-dione

6-acetyl-1,3-dimethylpteridine-2,4-dione

C10H10N4O3 (234.0753)


   

6-(3-hydroxypropanoyl)-1,3-dimethylpteridine-2,4-dione

6-(3-hydroxypropanoyl)-1,3-dimethylpteridine-2,4-dione

C11H12N4O4 (264.0859)


   

6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-3h-purin-2-ol

6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-3h-purin-2-ol

C10H13N5O2 (235.1069)


   

3,9-dimethyl-6-(methylimino)purin-8-ol

3,9-dimethyl-6-(methylimino)purin-8-ol

C8H11N5O (193.0964)


   

6-[(1s)-1-hydroxypropyl]-1,3-dimethylpteridine-2,4-dione

6-[(1s)-1-hydroxypropyl]-1,3-dimethylpteridine-2,4-dione

C11H14N4O3 (250.1066)


   

3-hydroxy-6,8-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione

3-hydroxy-6,8-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione

C7H7N5O3 (209.0549)


   

2-methoxy-3h-purin-6-amine

2-methoxy-3h-purin-6-amine

C6H7N5O (165.0651)


   

1-(3-methylbut-2-en-1-yl)purin-6-amine

1-(3-methylbut-2-en-1-yl)purin-6-amine

C10H13N5 (203.1171)


   

2-{[4-({9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl}amino)-2-methylbut-2-en-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

2-{[4-({9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl}amino)-2-methylbut-2-en-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C21H31N5O10 (513.2071)


   

7-methyl-1,3-bis(3-methylbut-2-en-1-yl)purine-2,6-dione

7-methyl-1,3-bis(3-methylbut-2-en-1-yl)purine-2,6-dione

C16H22N4O2 (302.1743)


   

2-methyl-4-(9h-purin-6-ylamino)pent-2-en-1-ol

2-methyl-4-(9h-purin-6-ylamino)pent-2-en-1-ol

C11H15N5O (233.1277)


   

n-(3-methylbutan-2-yl)-9h-purin-6-amine

n-(3-methylbutan-2-yl)-9h-purin-6-amine

C10H15N5 (205.1327)


   

(2e,4r)-2-methyl-4-(9h-purin-6-ylamino)pent-2-en-1-ol

(2e,4r)-2-methyl-4-(9h-purin-6-ylamino)pent-2-en-1-ol

C11H15N5O (233.1277)


   

6-imino-1,3-dimethyl-9h-purin-2-one

6-imino-1,3-dimethyl-9h-purin-2-one

C7H9N5O (179.0807)


   

9-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6-hydroxy-3,7-dimethylpurine-2,8-dione

9-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6-hydroxy-3,7-dimethylpurine-2,8-dione

C17H24N4O3 (332.1848)


   

1,3-dimethyl-7-[(2e,6e,11z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]purine-2,6-dione

1,3-dimethyl-7-[(2e,6e,11z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]purine-2,6-dione

C27H40N4O3 (468.31)


   

1,1,1-trimethyl-n-{9-[(2r,3r,4r,5r)-5-{[(3-methylbut-3-en-1-yl)oxy]methyl}-3,4-bis[(trimethylsilyl)oxy]oxolan-2-yl]purin-6-yl}silanamine

1,1,1-trimethyl-n-{9-[(2r,3r,4r,5r)-5-{[(3-methylbut-3-en-1-yl)oxy]methyl}-3,4-bis[(trimethylsilyl)oxy]oxolan-2-yl]purin-6-yl}silanamine

C24H45N5O4Si3 (551.2779)


   

2,6-dimethyl-1h-pyrimido[5,4-e][1,2,4]triazine-3,5,7-trione

2,6-dimethyl-1h-pyrimido[5,4-e][1,2,4]triazine-3,5,7-trione

C7H7N5O3 (209.0549)


   

2-[(8-hydroxy-7-methylpurin-6-yl)amino]ethanesulfonic acid

2-[(8-hydroxy-7-methylpurin-6-yl)amino]ethanesulfonic acid

C8H11N5O4S (273.0532)


   

3,7,9-trimethylpurine-6,8-dione

3,7,9-trimethylpurine-6,8-dione

C8H10N4O2 (194.0804)


   

(2r,3r,4s,5r)-2-{6-[(furan-2-ylmethyl)amino]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol

(2r,3r,4s,5r)-2-{6-[(furan-2-ylmethyl)amino]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol

C15H17N5O5 (347.123)


   

2-(dimethylamino)-6-hydroxy-7,9-dimethyl-8h-purin-8-yl

2-(dimethylamino)-6-hydroxy-7,9-dimethyl-8h-purin-8-yl

C9H14N5O (208.1198)


   

5-{6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]purin-9-yl}-2-(hydroxymethyl)oxolan-3-ol

5-{6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]purin-9-yl}-2-(hydroxymethyl)oxolan-3-ol

C15H21N5O4 (335.1593)


   

1,3-dimethyl-6-propanoylpteridine-2,4-dione

1,3-dimethyl-6-propanoylpteridine-2,4-dione

C11H12N4O3 (248.0909)


   

(2e)-2-methyl-4-(9h-purin-6-ylamino)pent-2-en-1-ol

(2e)-2-methyl-4-(9h-purin-6-ylamino)pent-2-en-1-ol

C11H15N5O (233.1277)


   

2-{6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]purin-7-yl}-6-(hydroxymethyl)oxane-3,4,5-triol

2-{6-[(4-hydroxy-3-methylbut-2-en-1-yl)amino]purin-7-yl}-6-(hydroxymethyl)oxane-3,4,5-triol

C16H23N5O6 (381.1648)


   

2-imino-1,9-dimethyl-3h-purin-6-one

2-imino-1,9-dimethyl-3h-purin-6-one

C7H9N5O (179.0807)


   

6-amino-1,3-dimethylpurin-2-one

6-amino-1,3-dimethylpurin-2-one

C7H9N5O (179.0807)


   

2-methyl-4-(3h-purin-6-ylamino)but-2-en-1-ol

2-methyl-4-(3h-purin-6-ylamino)but-2-en-1-ol

C10H13N5O (219.112)


   

(2s)-2-{[(2r)-2-amino-1-hydroxypropylidene]amino}-4-(6-aminopurin-9-yl)butanoic acid

(2s)-2-{[(2r)-2-amino-1-hydroxypropylidene]amino}-4-(6-aminopurin-9-yl)butanoic acid

C12H17N7O3 (307.1393)


   

2-(3-methylbut-1-en-1-yl)-3h-purin-6-amine

2-(3-methylbut-1-en-1-yl)-3h-purin-6-amine

C10H13N5 (203.1171)


   

(2s,3r,4s,5r)-2-(6-{[(2z)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

(2s,3r,4s,5r)-2-(6-{[(2z)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.1543)


   

6-(3-methoxypropanoyl)-1,3-dimethylpteridine-2,4-dione

6-(3-methoxypropanoyl)-1,3-dimethylpteridine-2,4-dione

C12H14N4O4 (278.1015)


   

6-(3-methylbut-3-en-1-yl)purin-6-amine

6-(3-methylbut-3-en-1-yl)purin-6-amine

C10H13N5 (203.1171)


   

(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-({[(2r)-4-(3h-purin-6-ylamino)butan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-({[(2r)-4-(3h-purin-6-ylamino)butan-2-yl]oxy}methyl)oxane-3,4,5-triol

C16H25N5O6 (383.1805)


   

8-hydroxy-1-(3-oxobutyl)-9h-purin-6-one

8-hydroxy-1-(3-oxobutyl)-9h-purin-6-one

C9H10N4O3 (222.0753)


   

6-imino-3,7-dimethylpurin-2-ol

6-imino-3,7-dimethylpurin-2-ol

C7H9N5O (179.0807)


   

4-hydroxy-2-imino-7-methyl-1,5-dihydropteridin-6-one

4-hydroxy-2-imino-7-methyl-1,5-dihydropteridin-6-one

C7H7N5O2 (193.06)


   

6-amino-3-(3-methylbut-2-en-1-yl)-9h-purin-2-one

6-amino-3-(3-methylbut-2-en-1-yl)-9h-purin-2-one

C10H13N5O (219.112)


   

9-(3,7-dimethylocta-2,6-dien-1-yl)-6,8-dihydroxy-3-methylpurin-2-one

9-(3,7-dimethylocta-2,6-dien-1-yl)-6,8-dihydroxy-3-methylpurin-2-one

C16H22N4O3 (318.1692)


   

3-hydroxy-2,6,8-trimethyl-4a-(2-oxopropyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dione

3-hydroxy-2,6,8-trimethyl-4a-(2-oxopropyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dione

C11H15N5O4 (281.1124)


   

(2r,3s,4r,5r)-2-(6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-2-(methylsulfanyl)purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

(2r,3s,4r,5r)-2-(6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-2-(methylsulfanyl)purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C16H23N5O5S (397.142)


   

(2r,3r,4s,5s,6r)-2-(6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-9-yl)-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-(6-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]amino}purin-9-yl)-6-(hydroxymethyl)oxane-3,4,5-triol

C16H23N5O6 (381.1648)


   

2-imino-6-methoxy-7-methyl-3h-purin-8-ol

2-imino-6-methoxy-7-methyl-3h-purin-8-ol

C7H9N5O2 (195.0756)


   

3-(3-methylbut-2-en-1-yl)-9h-purin-6-imine

3-(3-methylbut-2-en-1-yl)-9h-purin-6-imine

C10H13N5 (203.1171)


   

6-hydroxy-7,9-dimethyl-2-(methylimino)-3,8-dihydropurin-8-yl

6-hydroxy-7,9-dimethyl-2-(methylimino)-3,8-dihydropurin-8-yl

C8H12N5O (194.1042)


   

7-hydroxy-6-methylpyrimido[5,4-e][1,2,4]triazin-5-one

7-hydroxy-6-methylpyrimido[5,4-e][1,2,4]triazin-5-one

C6H5N5O2 (179.0443)


   

trimethylimidazo[4,5-e][1,2,4]triazine-3,6-dione

trimethylimidazo[4,5-e][1,2,4]triazine-3,6-dione

C7H9N5O2 (195.0756)